Cormorant Asset Management, LP Rain Therapeutics Inc. Transaction History

Cormorant Asset Management, LP

  • $1.74 Billion
  • Q1 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023
BUY
$5.52 - $8.48 $3.6 Million - $5.53 Million
652,000 Added 28.02%
2,978,660 $23.8 Million
Q3 2021

Nov 15, 2021
SELL
$13.21 - $20.91 $3.96 Million - $6.27 Million
-300,000 Reduced 11.42%
2,326,660 $34.8 Million
Q2 2021

Aug 16, 2021
BUY
$15.08 - $20.3 $39.6 Million - $53.3 Million
2,626,660 New
2,626,660 $39.7 Million

Others Institutions Holding RAIN

# of Institutions
3
Shares Held
122K
Call Options Held
0
Put Options Held
0
View Full List

About Rain Therapeutics Inc.

RAIN Quotes by TradingView
  • Ticker RAIN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 18,837,400
  • Description
  • Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is milademetan, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing milademetan which is in...
More about RAIN
Track This Portfolio

Track Cormorant Asset Management, LP Portfolio

Follow Cormorant Asset Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cormorant Asset Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Cormorant Asset Management, LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email